KARYOPHARM Aktie

>KARYOPHARM Aktienkurs

0.705 EUR -9.0% (TradegateBSX)

Ask: 0.715 EUR / 4620 Stück

Bid: 0.71 EUR / 4650 Stück

Tagesumsatz: 2052 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

KARYOPHARM Aktie über LYNX handeln

Intraday

1 Jahr

>KARYOPHARM Performance

1 Woche: -50,5%

1 Monat: -53,6%

3 Monate: -91,6%

6 Monate: -86,2%

1 Jahr: -86,9%

laufendes Jahr: -88,7%

>KARYOPHARM Aktie

Profil:

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing therapies for cancer and other serious diseases. Karyopharm Therapeutics Inc. specializes in drugs that target nuclear e..
>Volltext..

Insiderhandel:

>KARYOPHARM Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>KARYOPHARM Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>KARYOPHARM Chart & Kurs - NASDAQ

>KARYOPHARM News

03.10.26 - 01:01	Insiderhandel: Chief Accounting Officer verkauft Aktien von Karyopharm Therapeutics im Wert von 450 USD (Insiderkauf)
	Abate, Kristin - Vorstand - Tag der Transaktion: 2026-10-01...

01.10.26 - 22:06	Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
	NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was......

03.09.26 - 03:02	Insiderhandel: Chief Accounting Officer verkauft Aktien von Karyopharm Therapeutics im Wert von 38 USD (Insiderkauf)
	Abate, Kristin - Vorstand - Tag der Transaktion: 2026-09-01...

01.09.26 - 22:09	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
	NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,850 restricted stock units (RSUs) to two newly-hired employees.......

31.08.26 - 13:36	Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis (PR Newswire)
	– sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has submitted......

28.08.26 - 00:30	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI (PR Newswire)
	NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.......

20.08.26 - 15:48	Karyopharm (KPTI) Q2 2026 Earnings Call Transcript (Fool)
	Biotech pivots to hematology after endometrial cancer setback, faces debt deadline....

13.08.26 - 19:03	Karyopharm outlines potential myelofibrosis approval and launch as early as Q1 2027 while targeting up to ~$1B in U.S. peak revenue (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.08.26 - 15:06	Karyopharm: Verlust im zweiten Quartal 2026 weitet sich aus, Liquiditätsdruck steigt (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

13.08.26 - 14:03	Karyopharm Therapeutics reports mixed Q2 results; reaffirms FY26 outlook (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.08.26 - 13:33	Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission (PR Newswire)
	– Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Remains on Track – – Planned sNDA for Selinexor plus Ruxolitinib Supported by Phase 3 SENTRY Results Presented at ASCO and EHA and Published in the......

12.08.26 - 18:27	Karyopharm Therapeutics Q2 2026 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

10.08.26 - 13:33	Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 (PR Newswire)
	-- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET -- NEWTON, Mass., Aug. 10, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second......

07.08.26 - 05:06	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI (PR Newswire)
	NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. ("Karyopharm" or the "Company") (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

31.07.26 - 16:30	Karyopharm Therapeutics: Aktie stürzt nach Fehlschlag bei Krebsstudie um über 60 % ab (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

31.07.26 - 02:01	Insiderhandel: EVP, Chief Development Officer verkauft Aktien von Karyopharm Therapeutics im Wert von 1342 USD (Insiderkauf)
	Poulton, Stuart - Vorstand - Tag der Transaktion: 2026-07-28...

31.07.26 - 01:45	Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.07.26 - 22:09	Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway (PR Newswire)
	– Company Plans to Submit sNDA in August 2026 and Will Request Priority Review – – Following FDA Engagements, Company Plans to Submit sNDA under Accelerated Approval Based Upon Compelling SVR35 Data and Preliminary Overall Survival Data Observed at the Time of the Topline Results – –......

30.07.26 - 22:06	Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer (PR Newswire)
	– The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) – – A Trend Favoring the Selinexor Arm was Observed with a 5.3 Month Improvement in Median PFS Relative to the Placebo Arm in the mITT Population; Company Plans to Continue to Follow Patients for Longer-Term......

22.07.26 - 15:15	Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
	Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wenn wir nur das Unrecht hassen und nicht diejenigen, die es tun, werden wir unsere Kampfgenossen und unsere Feinde lieben. - Freifrau Marie von Ebner-Eschenbach

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram